tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ciancio G et al. | The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. | 2003 | Am. J. Transplant. | pmid:12859538 |
| Xu H et al. | The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. | 2014 | Am. J. Transplant. | pmid:24472192 |
| Abdelmalek MF et al. | Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. | 2012 | Am. J. Transplant. | pmid:22233522 |
| Coghill AE et al. | Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. | 2016 | Am. J. Transplant. | pmid:26824445 |
| Knechtle SJ | Guidance for liver transplant immunosuppression. | 2011 | Am. J. Transplant. | pmid:21466652 |
| Saikali JA et al. | Sirolimus may promote thrombotic microangiopathy. | 2003 | Am. J. Transplant. | pmid:12603218 |
| Budde K et al. | Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. | 2014 | Am. J. Transplant. | pmid:25278376 |
| Duncan FJ et al. | Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. | 2007 | Am. J. Transplant. | pmid:17941958 |
| Hu X et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. | 2016 | Am. J. Transplant. | pmid:26749344 |
| Suszynski TM et al. | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. | 2013 | Am. J. Transplant. | pmid:23432755 |
| Ferguson R et al. | Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21114656 |
| McKenna G and Trotter JF | Does early (CNI) conversion lead to eternal (renal) salvation? | 2010 | Am. J. Transplant. | pmid:20928938 |
| Koefoed-Nielsen PB et al. | Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. | 2002 | Am. J. Transplant. | pmid:12099520 |
| Arnold R et al. | Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. | 2013 | Am. J. Transplant. | pmid:23841745 |
| Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
| Bryan CF et al. | Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. | 2007 | Am. J. Transplant. | pmid:17359511 |
| Vincenti F et al. | Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. | 2007 | Am. J. Transplant. | pmid:17359512 |
| Diaz-Siso JR et al. | Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. | 2015 | Am. J. Transplant. | pmid:25777324 |
| Klintmalm GB et al. | Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. | 2014 | Am. J. Transplant. | pmid:25041339 |
| TruneÄŒka P et al. | Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. | 2015 | Am. J. Transplant. | pmid:25707487 |
| Adam R et al. | Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. | 2015 | Am. J. Transplant. | pmid:25703527 |
| Asrani SK and O'Leary JG | Can one pill a day keep rejection away? | 2015 | Am. J. Transplant. | pmid:25703394 |
| Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
| Oetting WS et al. | Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. | 2016 | Am. J. Transplant. | pmid:26485092 |
| De Simone P et al. | Everolimus with reduced tacrolimus in liver transplantation. | 2013 | Am. J. Transplant. | pmid:23601137 |
| Badri P et al. | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. | 2015 | Am. J. Transplant. | pmid:25708713 |
| Chodoff L and Hamberg KJ | Response to 'Different preparations of tacrolimus and medication errors'. | 2009 | Am. J. Transplant. | pmid:19392982 |
| Cherukuri A et al. | An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. | 2012 | Am. J. Transplant. | pmid:22390816 |
| Barth RN et al. | Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. | 2011 | Am. J. Transplant. | pmid:21668624 |
| Chen G et al. | A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. | 2006 | Am. J. Transplant. | pmid:16539628 |
| Guirado L et al. | Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21668633 |
| Flechner SM et al. | The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. | 2011 | Am. J. Transplant. | pmid:21668635 |
| Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
| Carenco C et al. | Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. | 2015 | Am. J. Transplant. | pmid:25648361 |
| Maes BD et al. | Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. | 2002 | Am. J. Transplant. | pmid:12484345 |
| Heller T et al. | Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. | 2007 | Am. J. Transplant. | pmid:17532750 |
| Schrepfer S et al. | Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. | 2007 | Am. J. Transplant. | pmid:17532751 |
| Grenda R et al. | A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. | 2010 | Am. J. Transplant. | pmid:20420639 |
| Asberg A et al. | Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. | 2010 | Am. J. Transplant. | pmid:20486914 |
| Hautz T et al. | Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. | 2010 | Am. J. Transplant. | pmid:20353468 |
| Silva HT et al. | One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. | 2007 | Am. J. Transplant. | pmid:17217442 |
| Toso C et al. | Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. | 2006 | Am. J. Transplant. | pmid:16611343 |
| Lacaille F et al. | Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. | 2006 | Am. J. Transplant. | pmid:16611346 |
| Chamie K et al. | The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. | 2008 | Am. J. Transplant. | pmid:18853950 |
| Lefaucheur C et al. | Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. | 2008 | Am. J. Transplant. | pmid:18671673 |
| Pech T et al. | Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. | 2012 | Am. J. Transplant. | pmid:22974463 |
| McAlister VC et al. | Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. | 2006 | Am. J. Transplant. | pmid:16827858 |
| Gallon L et al. | Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. | 2006 | Am. J. Transplant. | pmid:16827862 |
| Grenda R et al. | A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. | 2006 | Am. J. Transplant. | pmid:16827869 |
| Lake JR et al. | Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. | 2005 | Am. J. Transplant. | pmid:16303011 |